Cancer Immunotherapy Trials Underutilize Immune Response Monitoring
| Autor: | Duncan I. Jodrell, Sophie E.M. Raby, Tobias Janowitz, Claire M. Connell, Thomas R. Flint, Douglas T. Fearon, Edward H. Williams, Ian Beh |
|---|---|
| Přispěvatelé: | Connell, Claire [0000-0002-6696-8415], Williams, Edward [0000-0001-9187-2258], Jodrell, Duncan [0000-0001-9360-1670], Apollo - University of Cambridge Repository |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Immune system Cancer immunotherapy response monitoring Monitoring Immunologic Neoplasms Internal medicine immune-related response criteria (irRC) medicine Humans Response criteria Immunity Cellular cancer immunotherapy business.industry Cancer T cell checkpoint inhibitor clinical trial Immunotherapy Prognosis medicine.disease 3. Good health Clinical trial Cross-Sectional Studies 030104 developmental biology 030220 oncology & carcinogenesis Immunology biomarker Biomarker (medicine) Therapeutic failure Brief Communications business |
| Zdroj: | The Oncologist |
| ISSN: | 1549-490X 1083-7159 |
| DOI: | 10.1634/theoncologist.2017-0226 |
| Popis: | This brief communication presents a quantitative assessment of the inclusion of immune‐related response criteria and immunological biomarker response monitoring in the registration details of T‐cell checkpoint‐targeted cancer immunotherapy trials in solid malignancies. Immune‐related radiological and biomarker monitoring in cancer immunotherapy trials permits interrogation of efficacy and reasons for therapeutic failure. We report the results from a cross‐sectional analysis of response monitoring in 685 T‐cell checkpoint‐targeted cancer immunotherapy trials in solid malignancies, as registered on the U.S. National Institutes of Health trial registry by October 2016. Immune‐related radiological response criteria were registered for only 25% of clinical trials. Only 38% of trials registered an exploratory immunological biomarker, and registration of immunological biomarkers has decreased over the last 15 years. We suggest that increasing the utilization of immune‐related response monitoring across cancer immunotherapy trials will improve analysis of outcomes and facilitate translational efforts to extend the benefit of immunotherapy to a greater proportion of patients with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text